CAR19 Tregs Treat Murine Chronic Graft-Versus-Host Disease through Immune Suppression in Absence of Measurable B-Cell Cytolysis

The authors evaluated human CD19-directed chimeric antigen receptor (CAR19) T cell therapy in a clinically relevant murine chronic Graft-Versus-Host disease model with bronchiolitis obliterans syndrome.